Zhong Li

Dr. Zhong Li

Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2022 in Journal of Ginseng Research
Verified
Journal Article
Open access
NWNi Wang
Ni Wang
JYJunyan Yang
Junyan Yang
RCRuijun Chen
Ruijun Chen
YLYunyun Liu
Yunyun Liu
SLShunjie Liu
Shunjie Liu
ZLZhong Li
Zhong Li
Alzheimer's disease (AD) is a common form of dementia, and impaired mitophagy is a hallmark of AD. Mitophagy is mitochondrial-specific autophagy. Ginsenosides from Ginseng involve in autophagy in cancer. Ginsenoside Rg1 (Rg1 hereafter), a single compound of Ginseng, has neuroprotective effects on AD. However, few studies have reported whether Rg1 can ameliorate AD pathology by regulating mitophagy. Human SH-SY5Y cell and a 5XFAD mouse model were used to investigate the effects of Rg1. Rg1 (1μM) was added to β-amyloid oligomer (AβO)-induced or APPswe-overexpressed cell models for 24 hours. 5XFAD mouse models were intraperitoneally injected with Rg1 (10 mg/kg/d) for 30 days. Expression levels of mitophagy-related markers were analyzed by western blot and immunofluorescent staining. Cognitive function was assessed by Morris water maze. Mitophagic events were observed using transmission electron microscopy, western blot, and immunofluorescent staining from mouse hippocampus. The activation of the PINK1/Parkin pathway was examined using an immunoprecipitation assay. Rg1 could restore mitophagy and ameliorate memory deficits in the AD cellular and/or mouse model through the PINK1-Parkin pathway. Moreover, Rg1 might induce microglial phagocytosis to reduce β-amyloid (Aβ) deposits in the hippocampus of AD mice. Our studies demonstrate the neuroprotective mechanism of ginsenoside Rg1 in AD models. Rg1 induces PINK-Parkin mediated mitophagy and ameliorates memory deficits in 5XFAD mouse models.

30 November 2019 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
SLShunjie Liu
Shunjie Liu
JPJunhao Pan
Junhao Pan
KTKe Tang
Ke Tang
QLQingfeng Lei
Qingfeng Lei
LHLu He
Lu He
ZLZhong Li
Zhong Li

1 January 2016 in Pharmacology Biochemistry and Behavior
Verified
Journal Article
Closed access
HZHualin Zhang
Hualin Zhang
ZLZhong Li
Zhong Li
ZZZhongliu Zhou
Zhongliu Zhou
HYHongyan Yang
Hongyan Yang
ZZZhiyong Zhong
Zhiyong Zhong
CLCaixia Lou
Caixia Lou

27 November 2013 in CNS Neuroscience & Therapeutics
Verified
Journal Article
Closed access
PDF file
YLYun‐Yun Liu
Yun‐Yun Liu
XYXing‐Yi Yang
Xing‐Yi Yang
ZLZhong Li
Zhong Li
ZLZhong‐Lin Liu
Zhong‐Lin Liu
DCDu Cheng
Du Cheng
HWHui‐Jun Wang
Hui‐Jun Wang

1 May 2017 in Journal of Pharmacological Sciences
Verified
Journal Article
Open access
HZHualin Zhang
Hualin Zhang
ZZZhongliu Zhou
Zhongliu Zhou
ZCZiming Chen
Ziming Chen
ZZZhiyong Zhong
Zhiyong Zhong
ZLZhong Li
Zhong Li
Depression is a common mental disorder and a leading cause of disability. At its most severe, it can lead to suicide. Recently, there has been growing interest in the application of natural herbs for the prevention and treatment of depression. In this report, we found that the ginsenoside active component Rg3 has an apparent antidepressant effect. In N-methyl-d-aspartic acid (NMDA)-treated HT22 murine hippocampal neuronal cells, Rg3 recovered proliferation and inhibited apoptosis by altering the cell cycle. More interestingly, Rg3 led to apparent physiological behavior change in a chronic mild stress model as seen in forced swim, tail suspension, and sucrose preference tests. This effect was mediated by the phosphorylation of cAMP response element binding protein (CREB) and brain-derived neurotrophic factor (BDNF) signaling. This study provides direct evidence to support the antidepressant effects of ginsenoside Rg3, potentially indicating its application in the treatment of clinical depression.

27 October 2015 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
HGHuimin Gao
Huimin Gao
XWXiaobo Wei
Xiaobo Wei
JLJinchi Liao
Jinchi Liao
RWRui Wang
Rui Wang
JXJiehua Xu
Jiehua Xu
Qing Dennis WangQing Dennis Wang
Qing Dennis Wang
Objectives Although several lines of evidence have suggested that patients with Parkinson’s disease (PD) have a higher risk of osteoporosis and fracture, the association between bone mineral density and severity of PD patients is unknown. Methods We performed a cross-sectional study of 54 patients with PD and 59 healthy age-matched controls. Multiple clinical scales were used to evaluate the severity of PD, and serum levels of calcium, phosphorus, and homocysteine were measured to determine bone mineral density’s association with PD severity. Results BMD in PD patients was significantly lower than in healthy controls. The BMD scores of the spine, femoral neck, and hip were lower in females than in males in the healthy group. In the PD group, BMD in the hip was significantly lower in females compared to males. There was a negative correlation between daily L-dopa dosage and BMD in the spine and hip in the PD group, while BMD in the spine, neck, and hip was significantly correlated with severity of PD. Besides, we found that among the lumbar spine, femoral neck and hip, bone loss in the lumbar spine was the most severe in PD patients based on the T-scores. Conclusions Our findings support the hypothesis that patients with PD have a higher risk of osteoporosis, and that low BMD in the spine, femoral neck, and hip may indirectly reflect the severity of PD. Our findings have prompted us to pay more attention to osteoporosis in the lumbar spine in Chinese PD patients.